How much of a biotech startup do the founders end up with after a number of funding rounds? It’s not simply a matter of how much money you’ve raised. Investor ownership, employee stock options, top ups to the option pool and convertible securities all play a part in how the equity is split as you move towards an IPO.
Generate Biomedicines offers a useful example. Its final IPO prospectus reported 102,450,201 shares of common stock outstanding after accounting for the conversion of preferred stock, including 69,333,244 shares issued upon that conversion. The company also had more than 20 million outstanding stock options.
These figures show how ownership becomes more complex as a biotech startup grows. And in 2026, that complexity matters even more as venture funding shifts toward later-stage companies.
In this article, we examine the latest biopharma funding trends, valuation signals, founder and investor ownership, employee option pools, shareholder counts, and dilution. We also explore what these trends mean for biotech founders preparing for their next financing round.
What Are the Biggest Biotech Ownership Trends in 2026?
Biotech startup ownership in 2026 is being shaped by larger funding rounds, a greater concentration of capital in later-stage companies, and the ongoing need to balance investor returns with employee incentives.
Key Findings
- Biopharma venture funding reached $23.9 billion across 385 rounds through Q3 2026, and Series B and later rounds took $17.3 billion of it, about 72%.
- The median early-stage biopharma round grew from $15 million in 2020 to $27 million in 2025, while early-stage funding fell from 44% to 32% of the total.
- Across all sectors, the PitchBook-NVCA Venture Monitor reports that the median Series D+ pre-money valuation more than doubled its 2025 level, and median deal value rose in every series except seed.
- Generate Biomedicines’ preferred stock converts into 69,333,244 shares at its IPO, and its 20,422,301 outstanding options carry a weighted average exercise price of $5.91.
- Options granted after December 31, 2025 averaged $11.75, and the IPO priced at $16.00 a share.
Why Biotech Funding Is Becoming More Selective in 2026
Biotech startups are still getting venture funding, but most of the money is going to a small number of companies. J.P. Morgan’s Q3 2026 biopharma report counts $23.9 billion raised across 385 venture rounds through the third quarter. By quarter, $9.9 billion was raised in Q2 and $6.7 billion in Q3.
The stage mix matters more than the total. Series B and later financings accounted for $17.3 billion across 215 rounds, about 72% of the capital, while seed and Series A rounds raised $6.6 billion. For ownership, this shift matters. When most of the money goes into later funding rounds, each company sells preferred stock to bigger investors sooner in its life.
Why Later Stage Valuations Are Matter for Biotech Founders
No public source publishes a clean median pre-money valuation for biotech startups alone, so this section separates what is biotech-specific from what is not.
What stands out in biotech is how big the funding rounds are. According to PitchBook data reported by Fierce Biotech, the median early-stage biopharma round grew from $15 million in 2020 to $27 million in 2025. Over the same period, early-stage funding fell from 44% to 32% of biopharma funding. Round sizes are rising while early-stage funding’s share of the total falls.
The all-sector data from the PitchBook-NVCA Venture Monitor (Q3 2026, as of September 30, 2026) points the same way, it states that the median Series D+ pre-money valuation more than doubles its 2025 level. It covers every venture-backed sector, not only biotech, so treat it as a market signal rather than a biotech benchmark.
Pre-money valuation is what a company is worth before a round’s new money arrives, and post-money is that figure plus the new money. For a biotech founder, the practical point is that valuation tends to track the asset’s stage, not revenue. A clinical-stage candidate generally prices above a discovery-stage one.
Founder Ownership: How Much Equity Remains as a Company Grows?
Private cap tables are not published, so the clearest evidence comes from companies that have filed to go public. Generate Biomedicines is a useful example. Flagship Pioneering incorporated it in 2018, and its S-1 describes a founding team led by co-founder Noubar Afeyan, with Gevorg Grigoryan as co-founder and CTO. Its founders therefore include a company builder, not only individual scientists.
As of December 31, 2025, the final prospectus reports 102,450,201 shares of common stock outstanding after giving effect to the conversion of preferred stock into 69,333,244 shares. Founders typically hold common stock, while investors hold preferred until it converts at the IPO, so the conversion line shows how much of the share count investors’ preferred stock represents.
Each priced round adds new shares, so founders’ percentages fall unless they buy more. Founder shares usually vest over time, which ties founders to the company through the clinical milestones that investors are funding.
Investor Ownership: Why Preferred Stock Holds Large Stakes
Investors in venture-backed biotechs hold preferred stock, which ranks ahead of common stock in a sale or liquidation and converts into common stock at an IPO. In the Generate prospectus, that conversion alone accounts for 69,333,244 shares. One company is not a market average, but the mechanics behind it are common in biotech financing.
Two features push investor ownership higher. First, rounds are large because trials are expensive, so each round buys a bigger slice. Second, rounds are often tranched, meaning investors commit the full amount but fund it in installments tied to clinical milestones. Ownership is usually set at the first closing, while the cash arrives later. A cap table can therefore show investor percentages that exceed the cash actually received so far.
Most biopharma venture capital in 2026 is later-stage money. J.P. Morgan reports that Series B and later rounds took $17.3 billion of 2026 biopharma venture funding, and that money arrives as preferred stock with liquidation preferences.
Employee Option Pool: Balancing Hiring Needs and Dilution
Stock options help biotech startups compete for scientific, technical, and executive talent without relying entirely on cash compensation.
Generate Biomedicines’ prospectus provides a useful illustration of how option arrangements evolve as a company approaches an IPO.
As of December 31, 2025, the company reported:
- 20,422,301 options outstanding under its 2019 plan.
- 3,404,855 shares reserved for future issuance under that plan.
- A $5.91 weighted average exercise price for outstanding options.
- An average exercise price of $11.75 for 441,076 options granted after December 31, 2025.
- An IPO price of $16 per share.
The company also disclosed that the reserved shares under its 2019 plan became unavailable when its 2026 Stock Option and Incentive Plan took effect.
These figures show why option pool planning matters. As a company advances, new grants may be issued at different exercise prices, showing changes in the fair market value of its common stock.
Number of Shareholders: No Public Median, but a Hard Ceiling
What is public is the legal ceiling on how many holders a private company can carry before it must report like a public one.
The SEC says a company with more than $10 million in total assets may have to register under the Exchange Act if a class of its equity is held on record by 2,000 or more persons, or by 500 or more persons who are not accredited investors. Persons who received securities under an employee compensation plan can be excluded from that count.
Three things add holders over time: investor syndicates that grow with each round and tranche, convertible note or SAFE holders who convert at a priced round, and employees who exercise options. Generate’s prospectus shows the layering. Its cap table carries four kinds of securities before the IPO adds public shareholders: preferred stock, common stock, options and a warrant. Record-holder counting rules have exceptions, so confirm them with securities counsel before a round adds many small holders.
Dilution: Each Round Adds Shares, and the Effect Compounds
Dilution is the share of the company that new investors take in a round. It depends on two inputs: how much money is raised and the valuation it is raised at. The same round size at a higher valuation sells a smaller share of the company, which is why both figures matter.
The Venture Monitor reports that median deal value continues to rise across all series except seed, and that the median Series D+ pre-money valuation more than doubles its 2025 level. Round size and valuation are the two inputs to dilution, so both movements matter to founders planning later rounds.
The cumulative effect is still large, because each round’s new shares reduce the percentage held by everyone who invested earlier. Option pool top-ups, convertible notes that convert at a priced round and tranched closings all add further dilution on top of the headline round. Founders can model this by running each expected round through a cap table before signing a term sheet.
What These Trends Mean for Your Cap Table
Think of a biotech founder planning the next two years. Three things in the 2026 data are worth acting on.
First, the option pool. Investors usually ask for it before their money comes in, so existing holders pay for it. Size it to the people you plan to hire before the next raise.
Second, the number of rounds. Round sizes are rising at every stage except seed, so each round takes a different share of the company. Put every round you expect into one cap table, with pool top-ups and notes, and look at where ownership ends up.
Third, timing. Generate’s options granted before 2026 averaged $5.91, and those granted after year-end averaged $11.75. The IPO then priced at $16.00. Options granted earlier were cheaper. A current 409A valuation keeps strike prices fair as milestones change the company’s value.
Last, the register. Investors, notes and option exercises all add names. The SEC’s 2,000-holder and 500 non-accredited-holder limits are easier to manage if you track the count from the first round.
FAQs
Still have questions about how biotech ownership works? Here are quick answers to a few common ones that the sections above don’t cover.
A down round prices shares below the last round, so more new shares are issued for the same money. Preferred holders with anti-dilution protection get their conversion price adjusted, which shifts the cost to common holders. Investors also often ask for a refreshed pool, which adds further dilution.
Yes, often. Investors want the team to stay through the clinical milestones with their money funds, so founder shares commonly vest over several years, sometimes with a cliff. Founders who already hold fully vested shares may be asked to re-vest part of them at a priced round.
Nobody owns the unissued part of the pool until options are granted, but it is normally counted in the fully diluted share total, so it reduces every existing holder’s fully diluted percentage from the day it is created.
As a right to buy shares at a fixed price, counted in the fully diluted total. Generate’s prospectus lists a warrant to purchase Series A preferred stock, with an aggregate exercise price of $150,000, which becomes a warrant for 98,749 common shares when the IPO is completed.
Plan Ownership Before the Next Biotech Funding Round
Biotech startup ownership is shaped by a series of connected decisions: when to raise capital, how much to raise, what valuation to accept, and how much equity to reserve for employees.
The 2026 data shows why these decisions matter. Approximately 72% of biopharma venture funding through Q3 went to Series B and later rounds, while larger financing rounds, option pool requirements, and convertible securities can all affect founders’ ownership over time.
The aim isn’t just to avoid dilution. You want to raise enough money, hire the right people, and hit your next milestone, all while knowing how each funding choice affects your current shareholders.
Before you sign your next term sheet, take time to model how the new funding will affect your fully diluted ownership. Keeping a clear and current cap table makes it easier to compare different options and get ready for talks with investors.
Eqvista helps private companies manage their capitalization tables and model ownership changes. Its 409A valuation services can also help US companies establish fair market value for common stock used in option pricing.
If you’re preparing for your next biotech funding round, explore Eqvista’s cap table management and 409A valuation services to support your equity planning.
